A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)

Stopped Early discontinuation based on strategic sponsor decision not driven by any safety concerns

Conditions

• Malignant Melanoma
• Squamous Cell Carcinoma of Skin

Interventions

• DRUG: THOR-707
• DRUG: Cemiplimab

Sponsor

Sanofi